Revvity secures FDA approval for improved automated latent tuberculosis test

Revvity, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT.TB test.

Key features of the automated latent tuberculosis test

• The Auto-Pure 2400 system seamlessly integrates liquid handling and magnetic cell isolation technology.
• The Auto-Pure 2400 system streamlines lab workflows, testing up to 24 samples per run, completing Day 1 of the T-SPOT.TB testing in under 3.5 hours with only a single mid-run user interaction.
• The WHO identifies T-SPOT.TB as the only ELISPOT-based IGRA. This methodology, with its added cell number normalization step, ensures reproducible results by minimizing the impact of pre-analytical variables seen in other IGRAs.
• The T-SPOT.TB test delivers key advantages, including fewer indeterminate results, reduced need for repeat testing, and consistent performance in immunocompromised patients.

For In Vitro Diagnostic Use. Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.

Revvity release